Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.

A chemotherapy-free combination of HRS-4642 and adebrelimab shows a 43.2% objective response rate in previously treated metastatic KRAS G12D-mutant pancreatic ductal adenocarcinoma.

• Why it matters: KRAS G12D mutations promote an immunosuppressive tumor environment and are present in about 40% of PDAC cases, highlighting the need for effective targeted therapies in this difficult-to-treat cancer.
• What they did: The phase 1/2 trial involved 48 pretreated patients, establishing the recommended phase 2 dose with no dose-limiting toxicities, and assessing safety and efficacy through response rates, disease control, and survival metrics.
• The result: The regimen was well tolerated, with a median overall survival of 11.5 months and a median progression-free survival of 5.7 months, indicating promising antitumor activity that supports further research.